SCHEMBL6054648

SCHEMBL6054648

COCNC(=O)c1ccc2c(c1)n(C)c(=O)n2C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPD P32754 5/20 0.46
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ BRPF1 P55201 4/20 0.42
▸ BRD4 O60885 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ SLC22A12 Q96S37 1/20 0.41
▸ PIK3CA P42336 1/20 0.40
▸ GLA P06280 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ TP53 P04637 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ NR0B1 P51843 1/20 0.38
▸ ACSS2 Q9NR19 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30048876 0.82 HPD (0.52) HPDSMN1; SMN2MEN1KMT2AATM
SCHEMBL24815337 0.82 HPD (0.52) HPDSMN1; SMN2MEN1KMT2AATM
SCHEMBL30049030 0.77 SLC22A12 (0.57) HPDSMN1; SMN2MEN1KMT2AATM
SCHEMBL24812336 0.77 HPD (0.55) HPDSMN1; SMN2MEN1KMT2AATM
SCHEMBL24815336 0.77 SLC22A12 (0.57) HPDSMN1; SMN2MEN1KMT2AATM
SCHEMBL6054640 0.77 POLB (0.63) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL5836092 0.77 HPD (0.50) HPDSMN1; SMN2ALDH1A1PIK3CATSHR
SCHEMBL25139664 0.77 HPD (0.52) HPDSMN1; SMN2BRPF1BRD4ALDH1A1
SCHEMBL25139613 0.76 HPD (0.54) HPDSMN1; SMN2MEN1KMT2AATM
SCHEMBL6054650 0.75 HPD (0.48) HPDSMN1; SMN2MEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1708709-A1 METHODS OF TREATING ACUTE INFLAMMATION IN ANIMALS WITH p38 MAP KINASE INHIBITORS Pfizer Products Incorporated (US) 2006-10-11 — — EP disclosed
US-20050153985-A1 Methods of treating acute inflammation in animals with p38 map kinase inhibitors KEHRLI MARCUS E JR (US) 2005-07-14 — — US disclosed
WO-2005060967-A1 METHODS OF TREATING ACUTE INFLAMMATION IN ANIMALS WITH p38 MAP KINASE INHIBITORS PFIZER PRODUCTS INC. (US) 2005-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153985-A1 Methods of treating acute inflammation in animals with p38 map kinase inhibitors MAPK1, MAPKAPK2, MAP3K2 HPD 3336/4885SMN1; SMN2 4199/4885MEN1 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback